Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents

Tatsuhiko Azegami, Yoshikazu Yuki, Kaori Hayashi, Akihito Hishikawa, Shin Ichi Sawada, Kazuya Ishige, Kazunari Akiyoshi, Hiroshi Kiyono, Hiroshi Itoh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To combat global increases in the prevalence of lifestyle-related diseases and concomitant infectious diseases, we aimed to develop an innovative intranasal vaccine that simultaneously targets both hypertension and pneumonia, is not given by invasive injection, and offers prolonged therapeutic effect and reduced frequency of administration. Methods: Angiotensin II type 1 receptor-pneumococcal surface protein A (AT1R-PspA) vaccine, consisting of a cationic nanometer-sized hydrogel incorporating AT1R partial peptide conjugated with PspA and cyclic diguanylate monophosphate adjuvant, was created and given intranasally to spontaneously hypertensive rats (SHRs). Antigen-specific antibodies and blood pressure were examined to evaluate immune responses and the antihypertensive effect of the vaccine. To examine the protective effect of antibodies induced by vaccination on pneumococcal infection, sera obtained from immunized SHRs were incubated with a lethal dose of Streptococcus pneumoniae and then administered to mice. Results: Five doses of AT1R-PspA nasal-vaccine-induced AT1R-specific serum IgG antibody production and attenuated the development of hypertension in SHRs in the long term. Both in-vitro and in-vivo studies revealed that responses to angiotensin II were suppressed in vaccinated rats. Mice passively immunized with sera obtained from AT1R-PspA-vaccinated SHRs were protected from lethal pneumococcal infection. Conclusion: Intranasal immunization with AT1R-PspA vaccine has the potential to simultaneously attenuate the development of hypertension and protect from lethal pneumococcal infection.

Original languageEnglish
Pages (from-to)387-394
Number of pages8
JournalJournal of Hypertension
Volume36
Issue number2
DOIs
Publication statusPublished - 2018 Feb 1

Fingerprint

Pneumococcal Infections
Angiotensin Type 1 Receptor
Inbred SHR Rats
Rodentia
Vaccination
Vaccines
Hypertension
Serum
Antibodies
Hydrogel
Therapeutic Uses
Streptococcus pneumoniae
Nose
Angiotensin II
Antihypertensive Agents
Antibody Formation
Communicable Diseases
Life Style
Immunization
Pneumonia

Keywords

  • angiotensin
  • hypertension
  • immunization
  • nasal vaccine
  • pneumonia

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents. / Azegami, Tatsuhiko; Yuki, Yoshikazu; Hayashi, Kaori; Hishikawa, Akihito; Sawada, Shin Ichi; Ishige, Kazuya; Akiyoshi, Kazunari; Kiyono, Hiroshi; Itoh, Hiroshi.

In: Journal of Hypertension, Vol. 36, No. 2, 01.02.2018, p. 387-394.

Research output: Contribution to journalArticle

Azegami, Tatsuhiko ; Yuki, Yoshikazu ; Hayashi, Kaori ; Hishikawa, Akihito ; Sawada, Shin Ichi ; Ishige, Kazuya ; Akiyoshi, Kazunari ; Kiyono, Hiroshi ; Itoh, Hiroshi. / Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents. In: Journal of Hypertension. 2018 ; Vol. 36, No. 2. pp. 387-394.
@article{58bce5e38cd445828e35690896716e81,
title = "Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents",
abstract = "Objectives: To combat global increases in the prevalence of lifestyle-related diseases and concomitant infectious diseases, we aimed to develop an innovative intranasal vaccine that simultaneously targets both hypertension and pneumonia, is not given by invasive injection, and offers prolonged therapeutic effect and reduced frequency of administration. Methods: Angiotensin II type 1 receptor-pneumococcal surface protein A (AT1R-PspA) vaccine, consisting of a cationic nanometer-sized hydrogel incorporating AT1R partial peptide conjugated with PspA and cyclic diguanylate monophosphate adjuvant, was created and given intranasally to spontaneously hypertensive rats (SHRs). Antigen-specific antibodies and blood pressure were examined to evaluate immune responses and the antihypertensive effect of the vaccine. To examine the protective effect of antibodies induced by vaccination on pneumococcal infection, sera obtained from immunized SHRs were incubated with a lethal dose of Streptococcus pneumoniae and then administered to mice. Results: Five doses of AT1R-PspA nasal-vaccine-induced AT1R-specific serum IgG antibody production and attenuated the development of hypertension in SHRs in the long term. Both in-vitro and in-vivo studies revealed that responses to angiotensin II were suppressed in vaccinated rats. Mice passively immunized with sera obtained from AT1R-PspA-vaccinated SHRs were protected from lethal pneumococcal infection. Conclusion: Intranasal immunization with AT1R-PspA vaccine has the potential to simultaneously attenuate the development of hypertension and protect from lethal pneumococcal infection.",
keywords = "angiotensin, hypertension, immunization, nasal vaccine, pneumonia",
author = "Tatsuhiko Azegami and Yoshikazu Yuki and Kaori Hayashi and Akihito Hishikawa and Sawada, {Shin Ichi} and Kazuya Ishige and Kazunari Akiyoshi and Hiroshi Kiyono and Hiroshi Itoh",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/HJH.0000000000001519",
language = "English",
volume = "36",
pages = "387--394",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents

AU - Azegami, Tatsuhiko

AU - Yuki, Yoshikazu

AU - Hayashi, Kaori

AU - Hishikawa, Akihito

AU - Sawada, Shin Ichi

AU - Ishige, Kazuya

AU - Akiyoshi, Kazunari

AU - Kiyono, Hiroshi

AU - Itoh, Hiroshi

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objectives: To combat global increases in the prevalence of lifestyle-related diseases and concomitant infectious diseases, we aimed to develop an innovative intranasal vaccine that simultaneously targets both hypertension and pneumonia, is not given by invasive injection, and offers prolonged therapeutic effect and reduced frequency of administration. Methods: Angiotensin II type 1 receptor-pneumococcal surface protein A (AT1R-PspA) vaccine, consisting of a cationic nanometer-sized hydrogel incorporating AT1R partial peptide conjugated with PspA and cyclic diguanylate monophosphate adjuvant, was created and given intranasally to spontaneously hypertensive rats (SHRs). Antigen-specific antibodies and blood pressure were examined to evaluate immune responses and the antihypertensive effect of the vaccine. To examine the protective effect of antibodies induced by vaccination on pneumococcal infection, sera obtained from immunized SHRs were incubated with a lethal dose of Streptococcus pneumoniae and then administered to mice. Results: Five doses of AT1R-PspA nasal-vaccine-induced AT1R-specific serum IgG antibody production and attenuated the development of hypertension in SHRs in the long term. Both in-vitro and in-vivo studies revealed that responses to angiotensin II were suppressed in vaccinated rats. Mice passively immunized with sera obtained from AT1R-PspA-vaccinated SHRs were protected from lethal pneumococcal infection. Conclusion: Intranasal immunization with AT1R-PspA vaccine has the potential to simultaneously attenuate the development of hypertension and protect from lethal pneumococcal infection.

AB - Objectives: To combat global increases in the prevalence of lifestyle-related diseases and concomitant infectious diseases, we aimed to develop an innovative intranasal vaccine that simultaneously targets both hypertension and pneumonia, is not given by invasive injection, and offers prolonged therapeutic effect and reduced frequency of administration. Methods: Angiotensin II type 1 receptor-pneumococcal surface protein A (AT1R-PspA) vaccine, consisting of a cationic nanometer-sized hydrogel incorporating AT1R partial peptide conjugated with PspA and cyclic diguanylate monophosphate adjuvant, was created and given intranasally to spontaneously hypertensive rats (SHRs). Antigen-specific antibodies and blood pressure were examined to evaluate immune responses and the antihypertensive effect of the vaccine. To examine the protective effect of antibodies induced by vaccination on pneumococcal infection, sera obtained from immunized SHRs were incubated with a lethal dose of Streptococcus pneumoniae and then administered to mice. Results: Five doses of AT1R-PspA nasal-vaccine-induced AT1R-specific serum IgG antibody production and attenuated the development of hypertension in SHRs in the long term. Both in-vitro and in-vivo studies revealed that responses to angiotensin II were suppressed in vaccinated rats. Mice passively immunized with sera obtained from AT1R-PspA-vaccinated SHRs were protected from lethal pneumococcal infection. Conclusion: Intranasal immunization with AT1R-PspA vaccine has the potential to simultaneously attenuate the development of hypertension and protect from lethal pneumococcal infection.

KW - angiotensin

KW - hypertension

KW - immunization

KW - nasal vaccine

KW - pneumonia

UR - http://www.scopus.com/inward/record.url?scp=85039729431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039729431&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000001519

DO - 10.1097/HJH.0000000000001519

M3 - Article

C2 - 28832363

AN - SCOPUS:85039729431

VL - 36

SP - 387

EP - 394

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 2

ER -